Are All Breast-fed Infants Equal? Clustering Metabolomics Data to Identify Predictive Risk Clusters for Childhood Obesity.


Journal

Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 26 10 2018
medline: 26 3 2020
entrez: 26 10 2018
Statut: ppublish

Résumé

Fetal and early life represent a period of developmental plasticity during which metabolic pathways are modified by environmental and nutritional cues. Little is known on the pathways underlying this multifactorial complex. We explored whether 6 months old breast-fed infants could be clustered into metabolically similar groups and that those metabotypes could be used to predict later obesity risk. Plasma samples were obtained from 183 breast-fed infants aged 6 months participating in the European multicenter Childhood Obesity Project study. We measured amino acids along with polar lipid concentrations (acylcarnitines, lysophosphatidylcholines, phosphatidylcholines, sphingomyelins). We determined the metabotypes using a Bayesian agglomerative clustering method and investigated the properties of these clusters with respect to clinical, programming, and metabolic factors up to 6 years of age. We identified 20 metabolite clusters comprising 1 to 39 children. Phosphatidylcholines predominantly influenced the clustering process. In the largest clusters (n ≥ 14), large differences existed for birth length (unadjusted P < 0.0001) and length and weight at 6 months (unadjusted P < 0.0001 and P = 0.012, respectively). Infants tended to cluster together by country (unadjusted P < 0.001). The body mass index (BMI) z score at 6 years of age tended to differ (unadjusted P = 0.07). Our exploratory study provided evidence that breast-fed infants are not metabolically homogeneous and that variation in metabolic profiles among infants may provide insight into later development and health. This work highlights the potential of metabotypes for identifying inter-individual differences that may form the basis for developing personalized early preventive strategies.

Identifiants

pubmed: 30358737
doi: 10.1097/MPG.0000000000002184
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

408-415

Auteurs

Franca Fabiana Kirchberg (FF)

Ludwig-Maximilians-Universität München, Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital, Munich, Germany.

Veit Grote (V)

Ludwig-Maximilians-Universität München, Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital, Munich, Germany.

Dariusz Gruszfeld (D)

Neonatal Intensive Care Unit, Children's Memorial Health Institute, Warsaw, Poland.

Piotr Socha (P)

Neonatal Intensive Care Unit, Children's Memorial Health Institute, Warsaw, Poland.

Ricardo Closa-Monasterolo (R)

Pediatric Nutrition and Development Research Unit, Universitat Rovira I Virgili, IISPV, Reus, Spain.

Joaquin Escribano (J)

Pediatric Nutrition and Development Research Unit, Universitat Rovira I Virgili, IISPV, Reus, Spain.

Elvira Verduci (E)

Department of Paediatrics, San Paolo Hospital, University of Milan, Milano, Italy.

Benedetta Mariani (B)

Department of Paediatrics, San Paolo Hospital, University of Milan, Milano, Italy.

Jean-Paul Langhendries (JP)

Centre Hospitalier Chrétien St Vincent, Liège-Rocourt, Belgium.

Pascale Poncelet (P)

Department of Pediatrics, University Children's Hospital Queen Fabiola, Université Libre de Bruxelles, Brussels, Belgium.

Berthold Koletzko (B)

Ludwig-Maximilians-Universität München, Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital, Munich, Germany.

Christian Hellmuth (C)

Ludwig-Maximilians-Universität München, Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH